Prof Choueiri presents results from the open label phase III clinical METEOR trial comparing cabozantinib with everolimus, the current standard treatment for kidney cancer, at a press conference at ECC 2015.

The trial compared cabozantinib with everolimus in more than 600 patients with metastatic renal cell carcinoma (mRCC) and found that the primary endpoint of progression-free survival was significantly prolonged with cabozantinib. Interim results showed a trends towards an overall survival benefit.

See the news story and watch the interview for more.

Watch Prof Martine Piccart comment on the research.